NASDAQ$NUWE
Nuwellis Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Nuwellis reported Q1 2026 revenue growth and completed the Rendiatech asset acquisition amid ongoing losses.
Nuwellis Inc. achieved net sales of $2.4 million in Q1 2026, up 26% year-over-year, driven by increased console and circuit sales in the U.S. market. The company recorded a net loss of $4.5 million and completed the Rendiatech acquisition, which added in-process R&D and monitoring technology to its cardiorenal platform. Cash position improved to $2.1 million following equity financing activities.
- Net sales rose 26% to $2.4 million with strong U.S. demand for Aquadex therapy.
- Gross margin expanded to 70.1% from 56.0% due to manufacturing transition.
- Completed Rendiatech asset acquisition adding kidney function monitoring technology.
- Raised $5.0 million gross via January private placement and warrant transactions.
Headline financials
Revenue & EPS history
Nuwellis · Revenue · Quarterly
$2.4M
Forward guidance
Company expects to fund operations into Q2 2026 with existing capital and will seek additional financing.
Tailwinds
- U.S. revenue growth momentum continuing
- Manufacturing cost improvements realized
Headwinds
- Substantial doubt about going concern status
- Need for additional capital to reach profitability
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-5.5%
Avg return
Earnings day
-10.5%
Avg return
5 days after
-16.7%
Avg return
30 days after
28%
15 / 54 earnings
Positive
+51.9%
Q1 2024
Best reaction
-29.9%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -5.0% | — | |
| Q4 2025 | +2.4% | -2.3% | -16.3% | |
| Q3 2025 | -3.4% | -11.9% | -18.0% | |
| Q2 2025 | +0.4% | +8.4% | -24.0% | |
| Q1 2025 | -3.1% | -5.1% | -68.7% | |
| Q4 2024 | -4.0% | -7.9% | -25.4% | |
| Q3 2024 | +6.6% | -0.6% | -28.2% | |
| Q2 2024 | -14.3% | -30.2% | -46.4% | |
| Q1 2024 | +51.9% | +47.1% | +29.4% | |
| Q4 2023 | -20.7% | -18.3% | -36.7% | |
| Q3 2023 | -10.0% | -12.9% | -14.3% | |
| Q2 2023 | -5.1% | -3.0% | -22.2% | |
| Q1 2023 | -29.9% | -37.8% | -34.6% | |
| Q4 2022 | -5.1% | -6.5% | -41.2% | |
| Q3 2022 | -19.6% | -16.7% | -50.0% | |
| Q2 2022 | -6.5% | -4.2% | +23.9% | |
| Q1 2022 | +1.0% | +2.9% | -7.4% | |
| Q4 2021 | -1.2% | -6.1% | +2.0% | |
| Q3 2021 | -17.0% | -13.2% | -33.3% | |
| Q2 2021 | +9.6% | +7.9% | +3.0% | |
| Q1 2021 | -14.6% | -8.9% | +6.6% | |
| Q4 2020 | +5.7% | -6.2% | -21.3% | |
| Q3 2020 | -7.8% | -7.0% | +14.1% | |
| Q2 2020 | -16.0% | -32.0% | -68.0% | |
| Q1 2020 | -9.6% | -14.6% | +2.4% | |
| Q4 2019 | -28.8% | -33.9% | -29.0% | |
| Q3 2019 | -15.0% | -23.0% | -16.0% | |
| Q2 2019 | -1.2% | +2.0% | +0.4% | |
| Q1 2019 | -13.3% | -13.3% | -24.9% | |
| Q4 2018 | -12.6% | -25.6% | -69.8% | |
| Q3 2018 | +2.8% | +4.7% | -21.7% | |
| Q2 2018 | -26.4% | -37.4% | -23.9% | |
| Q1 2018 | -17.1% | -18.8% | -23.3% | |
| Q4 2017 | -15.5% | -25.7% | -21.0% | |
| Q3 2017 | -12.8% | -15.6% | -47.3% | |
| Q2 2017 | -4.0% | -13.3% | -6.7% | |
| Q1 2017 | -9.5% | -1.4% | -9.5% | |
| Q4 2016 | -5.3% | -12.0% | -58.0% | |
| Q3 2016 | -5.0% | -5.0% | +190.0% | |
| Q2 2016 | -14.9% | -16.0% | -17.0% | |
| Q1 2016 | +1.5% | — | — | |
| Q4 2015 | -15.9% | — | — | |
| Q3 2015 | -1.2% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | -3.5% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -17.5% | — | — | |
| Q2 2014 | +23.9% | — | — | |
| Q1 2014 | +3.2% | — | — | |
| Q4 2013 | +2.1% | — | — | |
| Q1 2013 | +6.2% | — | — | |
| Q4 2012 | +2.6% | — | — | |
| Q2 2012 | -7.6% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro